Peter Bouwman

Peter Bouwman

Auto-generated profile, based on publicly available information

Peter Bouwman

Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2010 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
PBPeter Bouwman
Peter Bouwman
AAAmal Aly
Amal Aly
JEJose Miguel Escandell
Jose Miguel Escandell
MPMark Pieterse
Mark Pieterse
JBJirina Bartkova
Jirina Bartkova
JJJos Jonkers
Jos Jonkers
A transposon mutagenesis screen indicates that loss of 53BP1 expression rescues the clonal growth defect of BRCA1 null cells. 53BP1 deficiency is shown to abrogate the cell cycle arrest triggered in the absence of BRCA1 and to partially restore homologous recombination. The potential clinical implications of these findings are supported by the reduction of 53BP1 expression in sporadic triple-negative and BRCA-associated breast cancers. Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a consequence of impaired recombinatorial DNA repair. Here we identify p53-binding protein 1 (53BP1) as an essential factor for sustaining the growth arrest induced by Brca1 deletion. Depletion of 53BP1 abrogates the ATM-dependent checkpoint response and G2 cell-cycle arrest triggered by the accumulation of DNA breaks in Brca1-deleted cells. This effect of 53BP1 is specific to BRCA1 function, as 53BP1 depletion did not alleviate proliferation arrest or checkpoint responses in Brca2-deleted cells. Notably, loss of 53BP1 partially restores the homologous-recombination defect of Brca1-deleted cells and reverts their hypersensitivity to DNA-damaging agents. We find reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of our findings.

1 June 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CPConstantia Pantelidou
Constantia Pantelidou
OSOlmo Sonzogni
Olmo Sonzogni
MTMateus De Oliveria Taveira
Mateus De Oliveria Taveira
AMAnita K. Mehta
Anita K. Mehta
AKAditi Kothari
Aditi Kothari
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor–induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8+ T-cell infiltration and activation in vivo, and that CD8+ T-cell depletion severely compromises antitumor efficacy. Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models. CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo. These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC. Significance: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8+ T-cell recruitment and antitumor efficacy. The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer. This article is highlighted in the In This Issue feature, p. 681

23 March 2015 in Nature
Verified
Journal Article
Closed access
PDF file
GXGuotai Xu
Guotai Xu
JCJ. Ross Chapman
J. Ross Chapman
IBInger Brandsma
Inger Brandsma
JYJingsong Yuan
Jingsong Yuan
MMMartin Mistrik
Martin Mistrik
SRSven Rottenberg
Sven Rottenberg

24 August 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PBPeter Bouwman
Peter Bouwman
JJJos Jonkers
Jos Jonkers

1 July 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
LMLaurens A. van Meeteren
Laurens A. van Meeteren
PRPaula Ruurs
Paula Ruurs
CSCatelijne Stortelers
Catelijne Stortelers
PBPeter Bouwman
Peter Bouwman
MRMarga A. van Rooijen
Marga A. van Rooijen
JJJos Jonkers
Jos Jonkers
Autotaxin (ATX), or nucleotide pyrophosphatase-phosphodiesterase 2, is a secreted lysophospholipase D that promotes cell migration, metastasis, and angiogenesis. ATX generates lysophosphatidic acid (LPA), a lipid mitogen and motility factor that acts on several G protein-coupled receptors. Here we report that ATX-deficient mice die at embryonic day 9.5 (E9.5) with profound vascular defects in yolk sac and embryo resembling the Galpha13 knockout phenotype. Furthermore, at E8.5, ATX-deficient embryos showed allantois malformation, neural tube defects, and asymmetric headfolds. The onset of these abnormalities coincided with increased expression of ATX and LPA receptors in normal embryos. ATX heterozygous mice appear healthy but show half-normal ATX activity and plasma LPA levels. Our results reveal a critical role for ATX in vascular development, indicate that ATX is the major LPA-producing enzyme in vivo, and suggest that the vascular defects in ATX-deficient embryos may be explained by loss of LPA signaling through Galpha13.

1 September 2002 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
PBPeter Bouwman
Peter Bouwman
SPSJAAK PHILIPSEN
SJAAK PHILIPSEN